Vanguard Fiduciary Trust
GRCE

Vanguard Fiduciary Trust’s Grace Therapeutics GRCE Stock Holding History

Vanguard Fiduciary Trust’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9K Hold
8,750
– – ﹤0.01% 3993
2026
Q1 		$40.5K Buy
+8,750
New +$34.4K ﹤0.01% 3864

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.23B AUM 74.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust's GRCE Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Grace Therapeutics (GRCE) position steady in Q2 2026 at 8,750 shares worth $19.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3993.

Vanguard Fiduciary Trust first reported a position in GRCE in Q1 2026 and has held it in 2 quarters since. The position peaked at $40.5K in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Vanguard Fiduciary Trust held 8,750 shares of Grace Therapeutics worth $19.9K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Grace Therapeutics share count unchanged in Q2 2026.
  • Grace Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3993 holding.
  • Vanguard Fiduciary Trust first reported a position in Grace Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Grace Therapeutics position peaked at $40.5K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.